HighTower Advisors LLC Has $6,574,000 Stake in Viveve Medical, Inc. (VIVE)
HighTower Advisors LLC increased its stake in Viveve Medical, Inc. (NASDAQ:VIVE) by 39.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 910,632 shares of the company’s stock after buying an additional 259,861 shares during the period. HighTower Advisors LLC’s holdings in Viveve Medical were worth $6,574,000 at the end of the most recent quarter.
Viveve Medical, Inc. (NASDAQ:VIVE) traded up 0.20% on Friday, hitting $4.91. The stock had a trading volume of 845 shares. Viveve Medical, Inc. has a one year low of $4.02 and a one year high of $10.50. The stock’s 50 day moving average is $5.74 and its 200 day moving average is $6.16.
Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.02. Viveve Medical had a negative return on equity of 378.87% and a negative net margin of 330.23%. The firm had revenue of $1.85 million for the quarter, compared to analyst estimates of $1.70 million. Equities analysts predict that Viveve Medical, Inc. will post ($2.13) earnings per share for the current year.
WARNING: “HighTower Advisors LLC Has $6,574,000 Stake in Viveve Medical, Inc. (VIVE)” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this piece can be read at http://www.dailypolitical.com/2017/01/13/hightower-advisors-llc-has-6574000-stake-in-viveve-medical-inc-vive.html.
Several research firms have recently commented on VIVE. B. Riley reiterated a “buy” rating and set a $8.00 price target on shares of Viveve Medical in a report on Friday, November 18th. Ladenburg Thalmann began coverage on Viveve Medical in a report on Tuesday, September 20th. They set a “buy” rating and a $22.00 price target on the stock.
Viveve Medical Company Profile
Viveve Medical, Inc, formerly PLC Systems, Inc, designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office.
Want to see what other hedge funds are holding VIVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viveve Medical, Inc. (NASDAQ:VIVE).
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.